Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists

dc.contributor.author	Butler, H	en_US
dc.contributor.author	Korbonits, M	en_US
dc.date.accessioned	2016-06-07T09:24:37Z
dc.date.issued	2009-11	en_US
dc.date.submitted	2016-06-06T18:26:36.004Z
dc.identifier.issn	0804-4643	en_US
dc.identifier.uri	http://qmro.qmul.ac.uk/xmlui/handle/123456789/12711
dc.format.extent	655 - 662	en_US
dc.language.iso	en	en_US
dc.relation.ispartof	EUR J ENDOCRINOL	en_US
dc.rights	CC-BY
dc.subject	CB1 RECEPTOR ANTAGONIST	en_US
dc.subject	ACTIVATED PROTEIN-KINASE	en_US
dc.subject	DISTINCT NEURONAL SUBPOPULATIONS	en_US
dc.subject	RANDOMIZED CONTROLLED-TRIAL	en_US
dc.subject	ADULT-MOUSE FOREBRAIN	en_US
dc.subject	ACID AMIDE HYDROLASE	en_US
dc.subject	DIET-INDUCED OBESITY	en_US
dc.subject	ENDOCANNABINOID SYSTEM	en_US
dc.subject	FOOD-INTAKE	en_US
dc.subject	ENERGY-BALANCE	en_US
dc.title	Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists	en_US
dc.type	Article
dc.rights.holder	© 2009 European Society of Endocrinology
dc.identifier.doi	10.1530/EJE-09-0511	en_US
pubs.issue	5	en_US
pubs.notes	Not known	en_US
pubs.volume	161	en_US
qmul.funder	Metabolic effects of cannabinoids and ghrelin: mechanisms of AMPK modulation::Wellcome Trust	en_US